

Lower Drug Prices for 583K Virginians

If Virginia adopts Medicare's negotiated drug prices for state-regulated commercial insurance, an estimated **\$95 million per year** in drug spending savings would flow to marketplace enrollees, state employees, their families, and their plans — starting in 2027 once both negotiation rounds are in effect.

What HB 483 means for Virginia in dollars and people

\$95M

PER YEAR

583K

VIRGINIANS

\$164

PER ENROLLEE

Total drug spending reduction across Virginia's commercial health system

389K marketplace enrollees + 195K state employees & families

At counter savings + future premiums savings

Where the savings come from

Annual savings broken down by drug — Medicare's negotiated price (MFP) compared against estimated post-rebate commercial net prices, applied to Virginia commercial utilization.

Annual Savings by Drug

Each bar shows the estimated annual reduction in Virginia commercial drug spending if Medicare's negotiated price replaces the current commercial net price

■ Round 1 ■ Round 2

